** Shares of drug developer Wave Life Sciences WVE.O rise 3.6% to $13.40

** Co says it has regained full rights to WVE-006, its experimental genetic disorder therapy, from GSK GSK.L

** WVE plans to engage with the US FDA on a potential accelerated approval pathway, with regulatory feedback expected mid-2026 for the therapy

** Co is testing the therapy as a potential treatment to alpha-1 antitrypsin deficiency, a genetic disorder that can lead to serious lung and liver diseases due to low levels of the protein alpha-1 antitrypsin

** Data from its ongoing clinical trial testing WVE-006 is on track for Q1 of 2026, co says

** "Decision is due to strategic re-prioritization by partner GSK vs. data driven as no new data were disclosed"- Jefferies

** "We think it makes sense as GSK may be more interested in large indications, such as COPD"- Truist

** WVE rose 37.4% last year

(Reporting by Sneha S K)

((Sneha.SK@thomsonreuters.com))